Baxter International Inc. (BAX) AI Stock Analysis

Baxter International Inc. develops and provides healthcare products essential for medical treatments across approximately 100 countries. Founded in 1931 and based in Deerfield, Illinois, the company employs 37,500 people. Its product portfolio spans peritoneal and hemodialysis therapies, intravenous therapies, infusion pumps, and drug reconstitution devices. Baxter also provides inhaled anesthesia products, pharmacy compounding services, parenteral nutrition therapies, critical care equipment, and surgical biological products for hemostasis and tissue sealing. Additionally, the company offers continuous renal replacement therapies, intensive care organ support solutions, and connected care technologies for monitoring and diagnosis across hospitals, dialysis centers, nursing homes, and home settings.

Baxter generated revenue of $11.24B in FY2025, up 5.7% year-over-year, following $10.64B in FY2024 and $10.36B in FY2023. However, revenue experienced a 5-year CAGR of -0.7% from FY2020 to FY2025. Gross margin contracted to 30.1% in FY2025 from 37.5% in FY2024 and 40.1% in FY2023. Operating margin was -2.7% in FY2025, down from 0.1% in FY2024. The company reported net losses in three of the last four years, including -$957.0M in FY2025 and -$649.0M in FY2024, despite posting net income of $2.66B in FY2023. In the latest quarter ended June 30, 2026, quarterly revenue increased 5.3% year-over-year, while quarterly earnings grew 36.8%.

As of June 30, 2026, Baxter held $2.15B in cash and short-term investments against total debt of $9.67B, resulting in net debt of $7.52B. Shareholders' equity stood at $6.21B, yielding a debt-to-equity ratio of 1.56 and a current ratio of 1.95. In FY2025, the business generated $845.0M in operating cash flow and $323.0M in free cash flow, down from free cash flow of $559.0M in FY2024. Capital expenditures totaled $522.0M and cash dividends paid were $348.0M during FY2025, while share issuance brought in $30.0M.

Baxter traded at a forward P/E of 11.6x, below the 16.6x median of its S&P 500 Healthcare peers. Its enterprise value of $19.66B implies an EV-to-EBITDA multiple of 25.8x, compared to the peer median of 15.0x. The stock carries a price-to-sales multiple of 1.1x versus the sector peer median of 3.4x, and a price-to-book ratio of 2.0x. Baxter's 1-year return of 10.3% trailed the S&P 500 return of 16.8%, while its 5-year return of -65.0% significantly lagged the S&P 500 gain of 83.0%.

Baxter pays an annual forward dividend of $0.04 per share, translating to a dividend yield of 0.16% and a payout ratio of 1.9%. The company has paid dividends for 45 consecutive years, distributing payments quarterly. Its annualized 5-year dividend growth rate was -11.4%. The most recent ex-dividend date was August 28, 2026.

Wall Street coverage consists of 2 Strong Buy ratings, 11 Hold ratings, and 1 Sell rating. The mean price target of $27.92 reflects 10.4% upside compared to the October 16, 2026 close of $25.28. For the fiscal year ending December 31, 2026, analysts estimate EPS of $2.05 on revenue of $11.62B. For the next fiscal year, 14 analysts project EPS of $2.04 and revenue of $11.87B. Baxter beat EPS estimates in 3 of the last 4 quarters, with next earnings scheduled for October 29, 2026.

This page is an AI-written research summary of Baxter International Inc. (BAX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: BAX income statement, BAX balance sheet, BAX key metrics, BAX analyst forecast, BAX chart. See the BAX stock overview for the latest quote and news.